|
C5ORF44 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.17720000309052E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.94639999859947E-08 |
| Normal-vs-Stage2 |
1.767810E-02 |
| Normal-vs-Stage3 |
1.19219999983322E-07 |
| Normal-vs-Stage4 |
4.62139992940536E-10 |
| Stage1-vs-Stage2 |
2.533400E-01 |
| Stage1-vs-Stage3 |
1.668980E-01 |
| Stage1-vs-Stage4 |
1.369950E-02 |
| Stage2-vs-Stage3 |
5.612300E-02 |
| Stage2-vs-Stage4 |
9.064100E-03 |
| Stage3-vs-Stage4 |
2.073800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.49789996967331E-09 |
| Normal-vs-AfricanAmerican |
2.903700E-03 |
| Normal-vs-Asian |
1.84420000004515E-06 |
| Caucasian-vs-AfricanAmerican |
4.419600E-01 |
| Caucasian-vs-Asian |
9.391600E-01 |
| AfricanAmerican-vs-Asian |
4.698200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.59060000118438E-08 |
| Normal-vs-Female |
2.18339999968897E-07 |
| Male-vs-Female |
3.583400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.62100000036902E-07 |
| Normal-vs-Age(41-60Yrs) |
6.21920004384435E-09 |
| Normal-vs-Age(61-80Yrs) |
2.97390000003617E-06 |
| Normal-vs-Age(81-100Yrs) |
3.555800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.111200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.891600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.739800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.124400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.153200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.775400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.242630E-01 |
| Classical-VS-Follicular |
3.497200E-03 |
| Classical-VS-Other |
6.053800E-01 |
| Classical-VS-Normal |
4.5489999545012E-09 |
| Tall-VS-Follicular |
3.047100E-04 |
| Tall-VS-Other |
7.439400E-01 |
| Tall-VS-Normal |
9.31870000053792E-08 |
| Follicular-VS-Other |
2.469700E-02 |
| Follicular-VS-Normal |
3.381900E-02 |
| Other-VS-Normal |
4.635500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.35440000010357E-07 |
| Normal-vs-N1 |
2.67230000017271E-07 |
| N0-vs-N1 |
1.989400E-01 |
|
|
